Document is current
Any future updates will be listed below
-
Authors
Gupta, A. https://orcid.org/0000-0001-5614-2313
Das, R.
Reed, K.
Jeon, T. https://orcid.org/0000-0003-3840-5129
Nguyen, Q. T. C. https://orcid.org/0009-0006-6007-1988
Rudra, A. https://orcid.org/0000-0002-1704-5534
Ge, X.
Trongjit, S.
Vanrobaeys, Y. S.
Langer, R. https://orcid.org/0000-0003-4255-0492
Weissleder, R. https://orcid.org/0000-0003-0828-4143
Garris, C.
Anderson, D. G. https://orcid.org/0000-0001-5629-4798
- License Information
-
More Information
Article History
Received: 23 September 2025
Accepted: 31 March 2026
First Online: 13 May 2026
Competing interests
: D.G.A. has advised Alnylam, Sanofi, Translate Bio, oRNA Therapeutics and Combined Therapeutics. R.L. has advised Alnylam, Moderna and Combined Therapeutics. A list of entities with which R.L. is involved, compensated or uncompensated, is available online ( ). Patent applications covering aspects of this work have been filed by D.G.A., A.G., K.R., R.D., R.W. and C.G. The other authors declare no competing interests.
